Cargando…
Detection of von Hippel‐Lindau gene mutation in circulating cell‐free DNA for clear cell renal cell carcinoma
The therapeutic landscape of metastatic clear cell renal cell carcinoma (ccRCC) has rapidly expanded, and there is an urgent need to develop noninvasive biomarkers that can select an optimal therapy or evaluate the response in real time. To evaluate the clinical utility of circulating tumor DNA (ctD...
Autores principales: | Sumiyoshi, Takayuki, Yamasaki, Toshinari, Takeda, Masashi, Mizuno, Kei, Utsunomiya, Noriaki, Sakamoto, Hiromasa, Nakamura, Eijiro, Ogawa, Osamu, Akamatsu, Shusuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353948/ https://www.ncbi.nlm.nih.gov/pubmed/34009695 http://dx.doi.org/10.1111/cas.14972 |
Ejemplares similares
-
Functional and genomic characterization of patient‐derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma
por: Sakamoto, Hiromasa, et al.
Publicado: (2020) -
Clear cell chondrosarcoma in Von Hippel-Lindau disease
por: Dreijerink, Koen M. A., et al.
Publicado: (2019) -
CCL2 as a potential therapeutic target for clear cell renal cell carcinoma
por: Arakaki, Ryuichiro, et al.
Publicado: (2016) -
Von Hippel-Lindau Disease
por: Hes, Frederik J, et al.
Publicado: (2005) -
Von Hippel-Lindau Disease and the Eye
por: Karimi, Saeed, et al.
Publicado: (2020)